Anidulafungin, a new echinocandin: effectiveness and tolerability

Area of Science:

• Mycology
• Pharmacology
• Infectious Diseases

Background:

• Anidulafungin is a novel echinocandin antifungal agent.
• It exhibits potent in vitro activity against Aspergillus and Candida species.
• Activity includes strains resistant to conventional antifungals like fluconazole and amphotericin B.

Purpose of the Study:

• To evaluate the efficacy and safety of anidulafungin in treating fungal infections.
• To compare anidulafungin with fluconazole in a randomized clinical trial.
• To assess potential drug-drug interactions with other common antifungal and immunosuppressive agents.

Main Methods:

• In vitro susceptibility testing against Aspergillus and Candida species.
• Clinical trials for oesophageal candidiasis and candidaemia/invasive candidiasis.
• Randomized clinical trial comparing anidulafungin and fluconazole.
• Drug-drug interaction studies with amphotericin B, voriconazole, and ciclosporin.

Main Results:

• Anidulafungin demonstrated effectiveness in treating oesophageal candidiasis, including azole-refractory cases.
• Anidulafungin was found to be noninferior to fluconazole for candidaemia and invasive candidiasis.
• No significant drug-drug interactions or adverse events were observed with concomitant use of other agents.
• Anidulafungin exhibits an excellent safety profile, with rare liver enzyme alterations; slow infusion is advised.

Conclusions:

• Anidulafungin is an effective and safe option for treating serious and difficult-to-treat fungal infections.
• It provides a valuable alternative for patients with infections resistant to other antifungals.
• Early clinical experience supports its role in managing invasive fungal diseases.